ReviewBiomedicines2021

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.

Mohd Imran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.